Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Melatonin protects skin keratinocyte from hydrogen peroxide-mediated cell death via the SIRT1 pathway.

Lee JH, Moon JH, Nazim UM, Lee YJ, Seol JW, Eo SK, Lee JH, Park SY.

Oncotarget. 2016 Mar 15;7(11):12075-88. doi: 10.18632/oncotarget.7679.

2.

Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis.

Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E.

Inflamm Bowel Dis. 2016 Mar;22(3):607-14. doi: 10.1097/MIB.0000000000000597.

3.

Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer Cells.

Pathak R, Philizaire M, Mujtaba S.

Cancers (Basel). 2015 Aug 19;7(3):1622-42. doi: 10.3390/cancers7030854. Review.

4.

Sirtuin 1 suppresses nuclear factor κB induced transactivation and pro-inflammatory cytokine expression in cat fibroblast cells.

Ishikawa S, Takemitsu H, Habara M, Mori N, Yamamoto I, Arai T.

J Vet Med Sci. 2016 Jan;77(12):1681-4. doi: 10.1292/jvms.15-0245. Epub 2015 Jul 13.

5.

Sirtuin 1 signaling and alcoholic fatty liver disease.

You M, Jogasuria A, Taylor C, Wu J.

Hepatobiliary Surg Nutr. 2015 Apr;4(2):88-100. doi: 10.3978/j.issn.2304-3881.2014.12.06. Review.

6.

Sirtuins in epigenetic regulation.

Jing H, Lin H.

Chem Rev. 2015 Mar 25;115(6):2350-75. doi: 10.1021/cr500457h. Epub 2015 Jan 28. Review. No abstract available.

7.

NAD(+)-SIRT1 control of H3K4 trimethylation through circadian deacetylation of MLL1.

Aguilar-Arnal L, Katada S, Orozco-Solis R, Sassone-Corsi P.

Nat Struct Mol Biol. 2015 Apr;22(4):312-8. doi: 10.1038/nsmb.2990. Epub 2015 Mar 9.

8.

The promise and perils of HDAC inhibitors in neurodegeneration.

Didonna A, Opal P.

Ann Clin Transl Neurol. 2015 Jan;2(1):79-101. doi: 10.1002/acn3.147. Epub 2014 Dec 3. Review.

9.

Sirt1-deficient mice have hypogonadotropic hypogonadism due to defective GnRH neuronal migration.

Di Sante G, Wang L, Wang C, Jiao X, Casimiro MC, Chen K, Pestell TG, Yaman I, Di Rocco A, Sun X, Horio Y, Powell MJ, He X, McBurney MW, Pestell RG.

Mol Endocrinol. 2015 Feb;29(2):200-12. doi: 10.1210/me.2014-1228. Epub 2014 Dec 29.

10.

Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.

Di Sante G, Pestell TG, Casimiro MC, Bisetto S, Powell MJ, Lisanti MP, Cordon-Cardo C, Castillo-Martin M, Bonal DM, Debattisti V, Chen K, Wang L, He X, McBurney MW, Pestell RG.

Am J Pathol. 2015 Jan;185(1):266-79. doi: 10.1016/j.ajpath.2014.09.014.

11.

Sirtuin deacetylases: a new target for melanoma management.

Wilking MJ, Singh CK, Nihal M, Ndiaye MA, Ahmad N.

Cell Cycle. 2014;13(18):2821-6. doi: 10.4161/15384101.2014.949085.

12.

Understanding the acetylome: translating targeted proteomics into meaningful physiology.

Philp A, Rowland T, Perez-Schindler J, Schenk S.

Am J Physiol Cell Physiol. 2014 Nov 1;307(9):C763-73. doi: 10.1152/ajpcell.00399.2013. Epub 2014 Sep 3. Review.

13.

Histone deacetylase inhibitors and cell death.

Zhang J, Zhong Q.

Cell Mol Life Sci. 2014 Oct;71(20):3885-901. doi: 10.1007/s00018-014-1656-6. Epub 2014 Jun 5. Review.

14.

A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.

Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA, Wei SR, Pollio G, Magnoni L, Scali C, Massai L, Franceschini D, Camarri M, Gianfriddo M, Diodato E, Thomas R, Gokce O, Tabrizi SJ, Caricasole A, Landwehrmeyer B, Menalled L, Murphy C, Ramboz S, Luthi-Carter R, Westerberg G, Marsh JL.

Hum Mol Genet. 2014 Jun 1;23(11):2995-3007. doi: 10.1093/hmg/ddu010. Epub 2014 Jan 16.

15.

Deleted in breast cancer 1 (DBC1) protein regulates hepatic gluconeogenesis.

Nin V, Chini CC, Escande C, Capellini V, Chini EN.

J Biol Chem. 2014 Feb 28;289(9):5518-27. doi: 10.1074/jbc.M113.512913. Epub 2014 Jan 10.

16.

Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1.

Ren JH, Tao Y, Zhang ZZ, Chen WX, Cai XF, Chen K, Ko BC, Song CL, Ran LK, Li WY, Huang AL, Chen J.

J Virol. 2014 Mar;88(5):2442-51. doi: 10.1128/JVI.02861-13. Epub 2013 Dec 11.

17.

Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity.

Knight JR, Allison SJ, Milner J.

Open Biol. 2013 Nov 20;3(11):130130. doi: 10.1098/rsob.130130.

18.

The emerging and diverse roles of sirtuins in cancer: a clinical perspective.

Yuan H, Su L, Chen WY.

Onco Targets Ther. 2013 Oct 8;6:1399-416. doi: 10.2147/OTT.S37750. Review.

19.

Sirtuin deacetylases as therapeutic targets in the nervous system.

Langley B, Sauve A.

Neurotherapeutics. 2013 Oct;10(4):605-20. doi: 10.1007/s13311-013-0214-5. Review.

20.

The diversity of histone versus nonhistone sirtuin substrates.

Martínez-Redondo P, Vaquero A.

Genes Cancer. 2013 Mar;4(3-4):148-63. doi: 10.1177/1947601913483767.

Items per page

Supplemental Content

Write to the Help Desk